SPDR® S&P Pharmaceuticals ETF (XPH)
39.59
-0.22 (-0.55%)
USD |
NYSEARCA |
Sep 26, 16:00
Price Chart
Key Stats
Customize
| Expense Ratio | Discount or Premium to NAV | Total Assets Under Management | 30-Day Average Daily Volume |
|---|---|---|---|
| 0.35% | -0.03% | 205.94M | 41163.50 |
| Dividend Yield | Turnover Ratio | 1 Year Fund Level Flows | Max Drawdown (All) |
| 1.70% | 60.00% | 19.63M | Upgrade |
Basic Info
| Investment Strategy | |
| The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of an index derived from the pharmaceuticals segment of a U.S. total market composite index. In seeking to track the performance of the S&P Pharmaceuticals Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the pharmaceuticals segment of the S&P Total Market Index ("S&P TMI"). |
| General | |
| Security Type | Exchange-Traded Fund |
| Equity Style | Mid Cap/Blend |
| Fixed Income Style | -- |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Category Index | S&P 1500 Health Care TR |
| Prospectus Objective | Specialty - Health |
| Fund Owner Firm Name | SPDR State Street Global Advisors |
| Prospectus Benchmark Index | |
| S&P Pharms Select Industry TR USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
| Manager Tenure | |
| Michael Feehily | 10.84 yrs |
| Karl Schneider | 7.84 yrs |
| Keith Richardson | 5.66 yrs |
Net Fund Flows Versus Category
1 Month
% Rank:
--
--
Category Low
--
Category High
1 Year
% Rank:
12
19.63M
-3.245B
Category Low
7.378B
Category High
3 Months
% Rank:
--
--
Category Low
--
Category High
3 Years
% Rank:
--
--
Category Low
--
Category High
6 Months
% Rank:
--
--
Category Low
--
Category High
5 Years
% Rank:
--
--
Category Low
--
Category High
YTD
% Rank:
--
--
Category Low
--
Category High
10 Years
% Rank:
--
--
Category Low
--
Category High
As of August 31, 2022
Performance Versus Category
As of September 26, 2022. Returns for periods of 1 year and above are annualized.
Annual Total Returns Versus Peers
As of September 26, 2022.
Asset Allocation
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
| Cassava Sciences Inc | 4.71% | 45.85 | 1.46% |
| Bristol-Myers Squibb Co | 3.72% | 70.66 | 0.73% |
| Johnson & Johnson | 3.71% | 166.28 | 0.35% |
| Merck & Co Inc | 3.66% | 86.58 | 0.46% |
| Eli Lilly and Co | 3.62% | 310.20 | 0.88% |
| Perrigo Co PLC | 3.59% | 37.98 | 0.85% |
| Pacira BioSciences Inc | 3.50% | 52.68 | -0.34% |
| Royalty Pharma PLC Class A | 3.41% | 40.21 | 0.83% |
| Pfizer Inc | 3.40% | 44.31 | 1.10% |
| Zoetis Inc Class A | 3.37% | 149.74 | 0.77% |
News
Headline
Wire
Time (ET)
SA Breaking News
07/08 15:38
SA Breaking News
06/21 12:15
SA Breaking News
03/23 12:17
SA Breaking News
03/14 00:40
SA Breaking News
12/21 15:45
SA Breaking News
09/21 15:14
SA Breaking News
06/22 14:43
Basic Info
| Investment Strategy | |
| The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of an index derived from the pharmaceuticals segment of a U.S. total market composite index. In seeking to track the performance of the S&P Pharmaceuticals Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the pharmaceuticals segment of the S&P Total Market Index ("S&P TMI"). |
| General | |
| Security Type | Exchange-Traded Fund |
| Equity Style | Mid Cap/Blend |
| Fixed Income Style | -- |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Category Index | S&P 1500 Health Care TR |
| Prospectus Objective | Specialty - Health |
| Fund Owner Firm Name | SPDR State Street Global Advisors |
| Prospectus Benchmark Index | |
| S&P Pharms Select Industry TR USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
| Manager Tenure | |
| Michael Feehily | 10.84 yrs |
| Karl Schneider | 7.84 yrs |
| Keith Richardson | 5.66 yrs |
Fundamentals
| General | |
| Distribution Yield | Upgrade |
| Dividend Yield TTM (9-26-22) | 1.70% |
| 30-Day SEC Yield (9-23-22) | Upgrade |
| 7-Day SEC Yield | -- |
| Number of Holdings | Upgrade |
| Stock | |
| Weighted Average PE Ratio | 18.23 |
| Weighted Average Price to Sales Ratio | Upgrade |
| Weighted Average Price to Book Ratio | Upgrade |
| Weighted Median ROE | Upgrade |
| Weighted Median ROA | Upgrade |
| Forecasted Dividend Yield | Upgrade |
| Forecasted PE Ratio | Upgrade |
| Forecasted Price to Sales Ratio | Upgrade |
| Forecasted Price to Book Ratio | Upgrade |
As of September 23, 2022
Growth Estimates
Fund Details
| Key Dates | |
| Inception Date | 6/19/2006 |
| Last Annual Report Date | 6/30/2022 |
| Last Prospectus Date | 10/31/2021 |
| Attributes | |
| Enhanced Index Fund | No |
| Index Fund |
|
| Inverse Fund | No |
| Leveraged Fund | No |
| Fund of Funds | No |
| Currency Hedged Fund | No |
| Synthetic Replication Fund | No |
| Has Dividend Investment Plan | No |
| Socially Responsible Fund | No |
News
Headline
Wire
Time (ET)
SA Breaking News
07/08 15:38
SA Breaking News
06/21 12:15
SA Breaking News
03/23 12:17
SA Breaking News
03/14 00:40
SA Breaking News
12/21 15:45
SA Breaking News
09/21 15:14
SA Breaking News
06/22 14:43